Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Camrelizumab in R/M NPC
NCT04586088Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04586088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04586088.